Posted Jul. 22, 2013 at 5:10 p.m.

Premium Lock Trial results sends BioCryst stock surging 51% in heavy trading

Published: 2013-07-22 17:10:00
Updated: 2013-07-22 17:10:00

BioCryst BioCryst

BioCryst says its compound to treat hereditary angiodema, a rare genetic disease, performs well in Phase I trial and plans to advance it to Phase II....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders